The pharmaceutical industry’s competition-based model could be a real liability in the race to develop drugs and vaccines to combat COVID-19. A better approach would be for pharma companies and partners outside the industry to temporarily hit the pause button on their traditional ways of doing business and find new ways to work together, as some scientists are now advocating.
|Journal||MIT Sloan Management Review|
|Publication status||Published - 16 Apr 2020|
- Breakthrough Innovation